Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab / 대한내과학회지
Korean Journal of Medicine
; : 415-418, 2017.
Article
in En
| WPRIM
| ID: wpr-211162
Responsible library:
WPRO
ABSTRACT
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Prognosis
/
Radiotherapy
/
Hodgkin Disease
/
Drug Therapy
/
Electrons
/
Fever
/
Positron Emission Tomography Computed Tomography
Type of study:
Prognostic_studies
Limits:
Adolescent
/
Humans
/
Male
Language:
En
Journal:
Korean Journal of Medicine
Year:
2017
Document type:
Article